Emerging therapeutic agents for onychomycosis

Expert Opinion on Emerging Drugs

Volumn 12, Issue 3, 2007, Pages 345-353

  Piérard, Gérald E ^a   Arrese, Jorge E ^a   Quatresooz, Pascale ^a   Pierard Franchimont C ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

Allylamine; Azole; Dermatophyte; Fungus; Mold; Onychomycosis; Yeast

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALLYLAMINE DERIVATIVE; AMOROLFINE; AN 2690; ANTIFUNGAL AGENT; CASPOFUNGIN; CICLOPIROXOLAMINE; ECHINOCANDIN; ECONAZOLE; GRISEOFULVIN; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; MORPHOLINE DERIVATIVE; POSACONAZOLE; POTASSIUM IODIDE; PRAMICONAZOLE; PYRIDONE DERIVATIVE; PYRROLE DERIVATIVE; RAVUCONAZOLE; SERTACONAZOLE; TERBINAFINE; UNCLASSIFIED DRUG; UREA; VORICONAZOLE; NEW DRUG;

DEBRIDEMENT; DERMATOPHYTE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; HUMAN; MYCOSIS; ONYCHOMYCOSIS; OUTCOME ASSESSMENT; PREVALENCE; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL TECHNIQUE; TECHNOLOGY; TREATMENT OUTCOME; ANIMAL; CHEMISTRY; DRUG DESIGN; HAND DISEASE; ORAL DRUG ADMINISTRATION; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTIFUNGAL AGENTS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; ONYCHOMYCOSIS;

EID: 34748914217     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.3.345     Document Type: Review

References (75)

1. GHANNOUM MA, HAJJEH RA, SCHER R et al.: A large-scale North American study of fungi isolated from nails: the frequency of onychoycosis, fungal distribution, and antifungal susceptibility patterns. J. Am. Acad. Dermatol. (2000) 43:641-648.
2. GUPTA AK, JAIN HC, LYNDE CW et al.: Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J. Am. Acad. Dermatol. (2000) 43:244-248.
3. PIERARD GE: Onychomycosis and other superficial fungal infections on the foot in the elderly: a pan European survey. Dermatology (2001) 202:220-224.
4. BURZYKOWSKI T, MOLENBEGHS G, ABECK D et al.: High prevalence of foot diseases in Europe: results of the Achilles project. Mycoses (2003) 46:496-505.
5. TOSTI A, PIRACCINI BM, MARIANI R et al.: Are local and systemic conditions important for the development of onychomycoses. Eur. J. Dermatol. (1998) 1:41-44.
6. SIGURGEIRSSON B, STEINGRIMSSON O: Risk factors associated with onychomycosis. J. Eur. Acad. Dermatol. Venereol. (2004) 18:48-51.
7. GUPTA AK, HUMKE S: The prevalence and management of onychomycosis in diabetic patients. Eur. J. Dermatol. (2000) 10:379-384.
8. PIERARD GE, PIERARD-FRANCHIMONT C: The nail under fungal siege in patients with Type II diabetes mellitus. Mycoses (2005) 48:339-342.
9. GUPTA AK, LYNDE CW, JAIN HC et al.: A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br. J. Dermatol. (1997) 136:786-789.
10. LARSEN GK, HAEDERSDAL M, SVEJGAARD EL: The prevalence of onychomycosis in patients with psoriasis and other skin diseases. Acta Derm. Venereol. (2003) 83:206-209.
11. PIERARD-FRANCHIMONT C, ARRESE JE, HERMANNS-LÊ T, PIERARD GE: Epidemiology of onychomycosis assessed by histomycology in psoriatic patients. J. Mycol. Med. (2006) 16:159-162.
12. PIERARD GE, ARRESE JE, PIERARD-FRANCHIMONT C, QUATRESOOZ P: Onychomycosis in older patient. Aging Health (2006) 2:865-870.
13. PIERARD-FRANCHIMONT C, ARRESE JE, QUATRESOOZ P, PIERARD GE: Mycopsoriatic onychopathy. Rev. Med. Liège (In press).
14. GUPTA AK, GUPTA MA, SUMMERBELL RC et al.: The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J. Eur. Acad. Dermatol. Venereol. (2000) 14:466-469.
15. SAEZ DE OCARIZ M, ARENAS R, RANERO-JUAREZ GA: Frequency of toenail onychomycosis in patients with cutaneous manifestations of chronic venous insufficiency. Int. J. Dermatol. (2001) 40:18-25.
16. PIERARD GE: Spores, sporodochia and fomites in onychomycosis. Dermatology (2006) 213:169-172.
17. ARRESE JE, PIERARD-FRANCHIMONT C, PIERARD GE: Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient. Am. J. Dermatpathol. (1996) 18:196-198.
18. NUCCI M, ANAISSIE E: Cutaneous infections by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin. Infect. Dis. (2002) 35:909-920.
19. QUATRESOOZ P, PIERARD-FRANCHIMONT C, ARRESE JE, PIERARD GE: Clinico-pathological presentations of dermatomycosis in cancer patients. J. Eur. Acad. Dermatol. Venereol. (In press).
20. ARRESE JE, PIERARD-FRANCHIMONT C, PIERARD GE: A plea to bridge the gap between antifungals and onychomycosis management. Am. J. Clin. Dermatol. (2001) 2:281-284.
21. ARRESE JE, PIERARD GE: Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology (2003) 207:255-260.
22. POTTER LP, MATHIAS SD, RAUT M, KIANIFARD F, LANDSMAN A, TAVAKKOL A: The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. Dermatol. Treat. (2007) 18:46-52.
23. MUKHERJEE PK, LEIDICH SD, ISHAM I, LEITNER I, RYDER NS, GHANNOUM MA: Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob. Agents Chemother. (2003) 47:82-86.
24. FAVRE B, GHANNOUM MA, RYDER NS: Biochemical characterization of terbinafine-resistant Trichophyton rubrum isolates. Med. Mycol. (2004) 42:525-529.
25. BORGERS M, DEGREEF H, CAUWENBERGH G: Fungal infections of the skin: infection process and antimycotic therapy. Curr. Drug Targets (2005) 6:849-862.
26. MURDAN S: Drug delivery to the nail following topical application. Int. J. Pharmaceutics (2002) 236:1-26.
27. FLAGOTHIER C, PIERARD-FRANCHIMONT C, PIERARD GE: New insights in the effect of amorolfine nail lacquer. Mycoses (2005) 48:91-94.
28. ARRESE JE, DE DONCKER P, ODDS F, PIERARD GE: Reduction in the growth of non-dermatophyte moulds by itraconazole: evaluation by corneofungimetry bioassay. Mycoses (1998) 41:461-465.
29. OSBORNE CS, LEITNER I, FAVRE B, RYDER NS: Antifungal drug response in an in vitro model of dermatophyte nail infection. Med. Mycol. (2004) 42:159-163.
30. BARAN R, GUPTA AK, PIERARD GE: Pharmacotherapy of onychomycosis. Expert Opin. Pharmacother. (2005) 6:609-624.
31. PIERARD GE, PIERARD-FRANCHIMONT C, VROOME V, BORGERS M, CAUWENBERGH G: Established and emerging oral antifungals in dermatology. In: Dermatological and Cosmeceutical Development. Walters KA, Roberts MS (Eds), Publ. Marcel Dekker, New York, USA (In press).
32. PIERARD GE, ARRESE JE, PIERARD-FRANCHIMONT C: Treatment of onychomycosis. Traditional approaches. J. Am. Acad. Dermatol. (1993) 29:S41-S45.
33. DEGREEF H, HEERES J, BORGERS M: Antifungal azoles for skin disorders. Expert Opin. Ther. Patents (2006) 16:1235-1253.
34. PIERARD GE, ARRESE JE, DE DONCKER P: Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J. Am. Acad. Dermatol. (1995) 32:429-435.
35. PIERARD GE, ARRESE JE, PIERARD-FRANCHIMONT C: Itraconazole. Exp. Opin. Pharmacother. (2000) 1:287-304.
36. ARRESE JE, PIERARD-FRANCHIMONT C, PIERARD GE: Facing up to the diagnostic uncertainty and management of onychomycoses. Int. J. Dermatol. (1999) 38:S1-S6.
37. PIERARD GE, PIERARD-FRANCHIMONT C, ARRESE JE: The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology (2000) 200:185-187.
38. PIERARD GE, PIERARD-FRANCHIMONT C, ARRESE JE: The boosted antifungal topical treatment (BATT) for onychomycosis. Med. Mycol. (2000) 38:391-392.
39. GUPCHUP GV, ZATZ JL: Structural characteristics and permeability properties of the human nail: a review. J. Cosmet. Sci. (1999) 50:363-385.
40. KOBAYASHI Y, MIYAMOTO M, SUGIBAYASHI K, MORIMOTO Y: Drug permeation through the three layers of the human nail plate. J. Pharm. Pharmacol. (1999) 51:271-278.
41. PALMERI A, PICHINI S, PACIFICI R et al.: Drugs in nails: physiology, pharmacokinetics and forensic toxicology. Clin. Pharmacokinet. (2000) 38:95-110.
42. KOBAYASHI Y, KOMATSU T, SUMI M et al.: In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur. J. Pharm. Sci. (2004) 21:471-477.
43. HANEKE E, ROSEEUW D: The scope of onychomycosis: epidemiology and clinical features. Int. J. Dermatol. (1999) 38:7-12.
44. GIANNI C, MORELLI V, CERRI A et al.: Usefulness of histological examination for diagnosis of onychomycosis. Dermatology (2001) 202:283-288.
45. SUMMERBELL RC, COOPER E, BUNN U, JAMIESON F, GUPTA AK: Onychomycosis: a critical study of techniques and criteria for confirming the etiologic significance of nondermatophytes. Med. Mycol. (2005) 43:39-59.
46. PIERARD GE, QUATRESOOZ P, ARRESE JE: Spotlight on nail histomycology. Dermatol. Clin. (2006) 24:371-374.
47. BAKER SJ, HUI X, MAIBACH HI: Progress on new therapeutics for fungal nail infections. Ann. Ref. Med. Chem. (2005) 40:323-334.
48. PIERARD GE, PIERARD-FRANCHIMONT C, QUATRESOOZ P: Fungal thigmotropism in onychomycosis and in a clear hydrogel pad model. Dermatology (In press).
49. GHANNOUM MA, RICE LB: Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. (1999) 12:501-517.
50. VAN DE VELDE VJS, VAN PEER AP, HEYKANTS JJP et al.: Effects of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazole. Pharmacotherapy (1996) 16:424-428.
51. BARONE JA, MOSKOVITCH BL, GUARNIERI J et al.: Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob. Agents Chemother. (1998) 42:1862-1865.
52. MENICHETTI F, DEL FAVERO A, MARTINO P et al.: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin. Infect. Dis. (1998) 28:250-255.
53. GLASMACHER A, HALN C, MOLITOR E et al.: Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regiments using hydroxypropyl-β-cyclodextrin oral solution or coated-pellet capsules. Mycoses (1999) 42:591-600.
54. STEVENS DA: Itraconazole in cyclodextrin solution. Pharmacotherapy (1999) 19:603-611.
55. SUSILO R, KORTING HC, GREB W et al.: Nail penetration of sertaconazole with a sertaconazole-containing nail patch formulation. Am. J. Clin. Dermatol. (2006) 7:259-262.
56. FANG FC: Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. (1997) 99:2818-2825.
57. BAKER SJ, ZHANG YK, AKAMA T: Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2, 1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. J. Med. Chem. (2006) 49:4447-4450.
58. GUPTA AK, LYNDE CW, KONNIKOV N: Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse for the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. (2001) 44:485-491.
59. POLACK A: The past, present and future of antimycotic combination therapy. Mycoses (1999) 42:355-370.
60. SANTOS DA, HAMDAN JS: In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. Med. Mycol. (2006) 44:357-362.
61. LECHA M, ALSINA M, TORRES RODRIGUES JM et al.: An open-label, multicenter study of the combination of amorolfine nail lacquer and oral itraconazole compared with itraconazole alone in the treatment of severe toenail onychomycosis. Curr. Ther. Res. (2002) 63:366-379.
62. BARAN R, SIGURGEIRSSON B, SIDOU F, KERROUCHE N, LECHA M: Efficacy and safety of amorolfine nail lacquer with oral terbinafine vs oral terbinafine alone in the treatment of onychomycosis with matrix involvement. J. Eur. Acad. Dermatol. Venereol. (2005) 19(Suppl 2):P16-P40.
63. SANTOS DA, HAMDAN JS: In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. Med. Mycol. (2006) 44:357-362.
64. BARCHIESI F, ARZENI D, CAMILETTI V et al.: In vivo activity of posaconazole against clinical isolates of dermatophytes. J. Clin. Microb. (2001) 39:4208-4209.
65. GUPTA AK, KOHLI Y, BATRA R: In vivo activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med. Mycol. (2005) 43:179-185.
66. ODDS F, AUSMA J, VAN GERVEN F et al.: In vitro and in vivo activities of the novel azole antifungal agent R126638. Antimicrob. Agents Chemother. (2004) 48:388-391.
67. VANDEN BOSSCHE H, AUSMA J, BOHETS H et al.: The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum cams. Antimicrob. Agents Chemother. (2004) 48:3272-3278.
68. PIERARD-FRANCHIMONT C, AUSMA J, WOUTERS L et al.: Activity of the triazole antifungal R126638 as assessed by corneofungimerry. Skin Pharmacol. Physiol. (2006) 19:49-56.
69. GUPTA AK, TOMAS E: New antifungal agents. Dermatol. Clin. (2003) 21:565-576.
70. FUNG-TOME JC, HUEZKO E, MINASSIAN B, BONNER DP: In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agetns Chemother. (1998) 42:313-318.
71. GUPTA AK, LEONARDI C, STOLTZ RR et al.: A Phase I/II randomized, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J. Eur. Acad. Dermatol. (2005) 19:437-443.
72. PIERARD GE, ARRESE JE, QUATRESOOZ P, PIERARD-FRANCHIMONT C: Voriconazole (Vfen®). Rev. Med. Liège (2003) 58:351-355.
73. VAN LOO D: Voriconazole: an evaluation of activity and use. J. Infect. Dis. Pharmacother. (2003) 6:15-37.
74. FOSTEL JM, LARTEY PA: Emerging novel antifungal agents. Drug Discov. Today (2000) 5:25-32.
75. OHWADA J, TSUKAZAKI M, HAYASE T et al.: Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole. Bioorg. Med. Chem. Lett. (2003) 13:191-196.